Available in Mexico, Argentina, Chile
The study will enroll participants with moderate to severe uncontrolled asthma who are on
low-dose inhaled corticosteroid (ICS) - a long-acting beta-agonist (LABA) or
medium-to-high-dose ICS with or without LABA background treatment.
The study will be initiated by Lead-in pharmacokinetics (PK) cohort in asthma
participants. Participant will be randomised globally, including participants in Lead-in
PK cohort (2 arms) and in Part 1 of the study (2 arms).
In the Lead-in PK cohort, participants will be randomised to Atuliflapon or placebo
(recruitment completed).
In Part 1 of the study, participants will be stratified by geographical region, and
grouped based on high or low levels of biomarker at screening (Visit 1).
1Research sites
666Patients around the world